17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Identification of TCL1A as an immunohistochemical marker of adverse outcome in diffuse large B-cell lymphomas.

      International Journal of Oncology
      Adult, Aged, Female, Gene Expression, Gene Expression Profiling, Humans, Immunohistochemistry, Leukemia, B-Cell, diagnosis, genetics, Lymphoma, Large B-Cell, Diffuse, Male, Middle Aged, Oligonucleotide Array Sequence Analysis, Prognosis, Proto-Oncogene Proteins, analysis, immunology, Tissue Array Analysis, Transcriptional Activation, Tumor Markers, Biological

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We used a combination of DNA-microarray and tissue-microarray (TMA) analyses to identify markers that could be routinely used to predict the outcome of diffuse large-B-cell lymphoma (DLCL) patients. Gene expression profiling was performed using DNA-microarrays on 52 tumour biopsy samples [31 DLCL and 21 follicular lymphomas (FL)] from 48 patients (28 DLCL and 20 FL). T-cell leukemia/lymphoma-1A (TCL1A) mRNA overexpression was correlated with relapse in DLCL patients. TMA analysis was applied on a distinct series of 36 formalin-fixed, paraffin-embedded DLCL samples and showed that TCL1A immunoexpression was correlated with either higher relapse (p=0.02) or lower 5-year overall survival (p=0.009) rates. Moreover, the prognostic value of TCL1A was independent from IPI in our series. Our data suggest that TCL1A immunodetection is an independent marker of adverse outcome that could be used in routine settings for the management of DLCL patients.

          Related collections

          Author and article information

          Comments

          Comment on this article